Inotiv Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 delivered strong DSA growth and margin improvement, offset by RMS weakness from lower NHP volumes. Cost reduction and site optimization efforts are underway, with innovation and new collaborations supporting future growth. No formal FY 2026 guidance was provided.
Fiscal Year 2025
-
Q4 and full year 2025 saw strong revenue growth, especially in DSA, with improved margins and reduced losses. Operational efficiencies, site consolidations, and technology upgrades drove cost savings, while a cybersecurity incident had some impact but was managed effectively.
-
Q4 saw strong revenue and DSA award growth, with operational efficiencies from integration and site consolidation. Pricing has firmed, margins are improving, and NHP activity stabilized. Debt restructuring and cyber recovery efforts are ongoing, with systems fully restored.
-
Significant growth achieved through integration, operational optimization, and a focus on preclinical CRO services. Recent quarters saw strong DSA award growth and improved financial performance, with a clear path to long-term EBITDA targets. Customer-centric strategies and infrastructure investments underpin future expansion.
-
Revised summary: Integration of acquisitions and operational improvements have driven strong growth in DSA awards and margins, while RMS remains stable amid market shifts. Capacity supports near-term growth, and recent investments should yield efficiencies. The organization has shown resilience through a cyberattack and adapts to regulatory changes.
-
Q3 2025 revenue grew 23.5% year-over-year to $130.7M, with improved margins and narrowed net loss. DSA and RMS segments both saw strong growth, while management remains cautious amid elevated cancellations and macroeconomic risks.
-
Bookings and margins are improving, led by growth in discovery and enhanced client experience. RMS margins are recovering, NHP pricing has stabilized, and risk mitigation strategies are in place. Revenue and EBITDA growth depend on sustained momentum and proactive capital management.
-
Q2 FY2025 revenue rose 4.4% year-over-year to $124.3M, led by RMS growth from higher NHP sales, while DSA margins declined but quoting and awards activity was strong. Adjusted EBITDA improved to $8M, and a revised RMS optimization plan is expected to deliver higher savings sooner.
-
Q1 FY2025 revenue declined 11.5% year-over-year due to lower NHP pricing, with net loss widening to $27.6 million. Liquidity improved via a $27.5 million equity raise, and cost-saving initiatives are underway. Management expects revenue and margin growth for the rest of FY2025.
Fiscal Year 2024
-
Q4 2024 revenue rose 23% sequentially but fell 7.3% year-over-year, with margin pressure from high-cost NHP inventory. Management expects improved RMS margins and growth in 2025, driven by stronger NHP pre-sales and recurring services, though industry price pressures persist.
-
Revenue and margins declined sharply year-over-year due to lower NHP sales and pricing, but operational improvements, legal resolutions, and early signs of NHP market recovery position the company for a stronger Q4 and improved 2025 outlook.
-
Integration of acquisitions and new service launches have driven strong DSA growth, with new offerings now contributing up to 10% of sales. NHP supply has stabilized, but customer overbuying led to excess inventory and a shift toward long-term contracts. Small animal demand is down, but pricing remains stable.